Last 212.00 GBp
Change Today +6.00 / 2.91%
Volume 12.8K
SLN On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
210.00 GBp
Previous Close
206.00 GBp
Day High
212.00 GBp
Day Low
210.00 GBp
52 Week High
02/25/14 - 388.75 GBp
52 Week Low
06/17/14 - 190.00 GBp
Market Cap
110.2M
Average Volume 10 Days
15.3K
EPS TTM
-0.23 GBp
Shares Outstanding
52.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a biotechnology company, discovers, develops, and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases primarily in North America and the Asia/Pacific. It has AtuRNAi, an RNAi platform, which encompasses the generation of potent chemically stabilized siRNA molecules. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and DBTC delivery system, which delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma. Its products include Atu027, which is in a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as in a Phase Ib clinical trial for head and neck cancer; Atu111 that is in pre-clinical stage for the treatment of lung diseases; and Atu112, which is in the pre-clinical stage for the treatment of systemic disorders. The company is also developing products for immunotherapy. Silence Therapeutics plc has partnership and collaboration agreements with various pharmaceutical companies, including Pfizer/Quark Pharmaceuticals, Novartis, AstraZeneca, Dainippon Sumitomo Pharma Co., Ltd., InteRNA Technologies B.V., Mirna Therapeutics Inc., and miRagen Therapeutics, Inc. The company is based in London, the United Kingdom.

38 Employees
Last Reported Date: 06/4/14

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 70.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 119.0K GBP
Chief Operating Officer
Total Annual Compensation: 58.0K GBP
Chief Medical Officer and Director
Total Annual Compensation: 53.0K GBP
Compensation as of Fiscal Year 2013.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Silence Therapeutics plc reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported revenue of GBP 7,000 against GBP 41,000 for the same period in the last year. Operating loss was GBP 5,711,000 against GBP 3,451,000 for the same period in the last year. Loss for the period before taxation was GBP 5,624,000 against GBP 3,406,000 for the same period in the last year. Loss per basic and diluted ordinary equity share was 11.5 pence against 8.4 pence for the same period in the last year. Loss after taxation was GBP 5,624,000 against GBP 3,406,000 for the same period in the last year. Net cash outflow from operating activities was GBP 5,232,000 against GBP 2,934,000 for the same period in the last year. Additions to property, plant and equipment were GBP 59,000 against GBP 27,000 a year ago. Additions to intangible assets were GBP 1,000 against GBP 17,000 for the same period in the last year.

Silence Therapeutics plc Announces Resignation of Chief Operating Officer Annie Cheng from the Board

Silence Therapeutics plc announced that due to family commitments, Chief Operating Officer Annie Cheng has resigned from the Board, ahead of moving back to New York early next year.

Silence Therapeutics plc to Report First Half, 2014 Results on Sep 16, 2014

Silence Therapeutics plc announced that they will report first half, 2014 results on Sep 16, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 212.00 GBp +6.00

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.03 AUD -0.005
Galena Biopharma Inc $2.19 USD 0.00
Marina Biotech Inc $0.96 USD -0.04
Prosensa Holding NV $8.66 USD -0.07
Regulus Therapeutics Inc $7.02 USD -0.35
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,189.5x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,261.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.